Journal issues > Issue 1, February 2021 > Highlights in myelodysplastic syndrome

Highlights in myelodysplastic syndrome

SUMMARY

Myelodysplastic syndromes (MDS) are a very heterogeneous group of clonal disorders of hematopoietic stem cells that are associated with cytopenias and a propensity to evolve to AML. In the recent years, significant progresses have been achieved to better understand the diversity of clinical, cytogenetic, molecular and immunological factors that are bound to the prognosis and outcome of patients with MDS. Their implementation into conventional risk stratification models should further refine patient subgroups, improve predictive value for survival and provide a next-generation classification and prognostic system for these patients, in order to assist personal treatment decision.

(BELG J HEMATOL 2021;12(1):38-46)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top